QPPV.COM KNOWLEDGE ASSESSMENT

Deoxycholic Acid Injection (Kybella): Development, Safety Evolution and Pharmacovigilance

Test your understanding of the concepts covered by Deoxycholic Acid Injection (Kybella): Development, Safety Evolution and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A clinician proposes using deoxycholic acid injection to reduce fat in a patient's upper arm. Which interpretation best reflects the US evidence and product information described in the article?
Question 2 of 10 FDA identified 129 cases associated with use outside the submental region and 117 cases of unresolved injection-site nodules or masses. Which inference is appropriate?
Question 3 of 10 What is the most accurate interpretation of deoxycholic acid's biological history in the development of ATX-101?
Question 4 of 10 Which pair correctly matches a safety concern with a relevant clinical or pharmacovigilance consideration?
Question 5 of 10 A safety team operating in several countries receives an FDA communication about the September 2026 US label update. What is the most appropriate regulatory response?
Question 6 of 10 Why should the common local reactions observed in pivotal trials not be treated as a complete description of the product's lifetime safety profile?
Question 7 of 10 Which governance record would best support a traceable signal-management decision concerning persistent lesions?
Question 8 of 10 Why is dividing FDA's identified case counts by the number of Kybella vials sold generally insufficient to calculate incidence?
Question 9 of 10 Phase I data showed that mean plasma deoxycholic acid rose shortly after treatment and returned to endogenous baseline on average by 24 hours. What conclusion is best supported?
Question 10 of 10 A persistent injection-site nodule is reported after treatment that appears consistent with the US submental indication. How should the site of use affect pharmacovigilance assessment?

Select an answer to continue.

QPPV.com